| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
|
Panhaleux, Marion
|
|
|
160 |
C |
p. 134-139
|
artikel
|
| 2 |
Corrigendum to ‘Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study’ [European Journal of Cancer 154 (2021) 246-252]
|
Fazio, Nicola
|
|
|
160 |
C |
p. 289-290
|
artikel
|
| 3 |
Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128]
|
Gogas, Helen
|
|
|
160 |
C |
p. 287-288
|
artikel
|
| 4 |
Disease-specific outcomes after chimeric antigen receptor T-cell therapy
|
Lemoine, Jean
|
|
|
160 |
C |
p. 235-242
|
artikel
|
| 5 |
Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer
|
Peralta-Arrieta, Irlanda
|
|
|
160 |
C |
p. 189-205
|
artikel
|
| 6 |
Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System
|
Sun, Ximu
|
|
|
160 |
C |
p. 277-278
|
artikel
|
| 7 |
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis
|
Becerril-Gaitan, Andrea
|
|
|
160 |
C |
p. 243-260
|
artikel
|
| 8 |
Impact of reducing excess body weight and physical inactivity on cancer incidence in Germany from 2020 to 2050—a simulation model
|
Gredner, Thomas
|
|
|
160 |
C |
p. 215-226
|
artikel
|
| 9 |
Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review
|
Schneider, Lucas
|
|
|
160 |
C |
p. 80-91
|
artikel
|
| 10 |
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
|
Maio, Michele
|
|
|
160 |
C |
p. 1-11
|
artikel
|
| 11 |
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
|
Vogl, Ursula M.
|
|
|
160 |
C |
p. 24-60
|
artikel
|
| 12 |
Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study
|
Sekkate, Sakina
|
|
|
160 |
C |
p. 282-284
|
artikel
|
| 13 |
Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study
|
Shacham-Shmueli, Einat
|
|
|
160 |
C |
p. 285-286
|
artikel
|
| 14 |
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium
|
de Joode, Karlijn
|
|
|
160 |
C |
p. 261-272
|
artikel
|
| 15 |
Localised rhabdomyosarcoma in infants (<12 months) and young children (12–36 months of age) treated on the EpSSG RMS 2005 study
|
Slater, Olga
|
|
|
160 |
C |
p. 206-214
|
artikel
|
| 16 |
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol
|
Stutterheim, J.
|
|
|
160 |
C |
p. 72-79
|
artikel
|
| 17 |
Monitoring patients at risk for melanoma: May convolutional neural networks replace the strategy of sequential digital dermoscopy?
|
Winkler, Julia K.
|
|
|
160 |
C |
p. 180-188
|
artikel
|
| 18 |
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials
|
van Dam, Jacob L.
|
|
|
160 |
C |
p. 140-149
|
artikel
|
| 19 |
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
|
Fizazi, Karim
|
|
|
160 |
C |
p. 61-71
|
artikel
|
| 20 |
Overall survival for oncology drugs approved for genomic indications
|
Haslam, Alyson
|
|
|
160 |
C |
p. 175-179
|
artikel
|
| 21 |
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer
|
Pearson, Andrew DJ.
|
|
|
160 |
C |
p. 112-133
|
artikel
|
| 22 |
Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer
|
Mizugaki, Hidenori
|
|
|
160 |
C |
p. 227-234
|
artikel
|
| 23 |
Rare haematologic and neurologic drug reactions from immune checkpoint inhibition in a responding patient with metastatic anorectal mucosal melanoma
|
Qaiyumi, Sarah
|
|
|
160 |
C |
p. 273-276
|
artikel
|
| 24 |
Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials
|
Hopkins, Ashley M.
|
|
|
160 |
C |
p. 279-281
|
artikel
|
| 25 |
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
|
Schneeweiss, Andreas
|
|
|
160 |
C |
p. 100-111
|
artikel
|
| 26 |
The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study
|
Chargi, Najiba
|
|
|
160 |
C |
p. 92-99
|
artikel
|
| 27 |
The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples
|
Van Paemel, Ruben
|
|
|
160 |
C |
p. 12-23
|
artikel
|
| 28 |
Therapeutic vaccines for breast cancer: Has the time finally come?
|
Corti, Chiara
|
|
|
160 |
C |
p. 150-174
|
artikel
|
Tijdschrift beschrijving